BioLineRx in development pact with Genoscience

BioLineRx (NASDAQ, TASE:BLRX) has signed a worldwide, exclusive license agreement with France’s Genoscience to develop and commercialize BL-8020, an oral candidate for the treatment of Hepatitis C. BL-8020 has been developed for anti-viral therapy by Prof. Philippe Halfon, co-founder and president of Genoscience. Prof. Halfon is a founder of several biotechnology companies and is world [...]

Soricimed in-licenses peptide from UHN

Closely held Soricimed Biopharma has in-licensed a proprietary peptide from the University Health Network, which was developed by Dr. Mansoor Husain at his lab at the University of Toronto. “Dr. Husain looked at a series of cell lines and showed that the peptide was able to stop growth in cervical, bone and lung cancer cells,” [...]

Enzo to acquire rights to cervical cancer test

Enzo Biochem’s (NYSE:ENZ) clinical labs subsidiary has reached an agreement with IncellDx of Menlo Park, Calif. for the rights to market a proprietary laboratory test based on HPV OncoTect, an advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer. The test will further [...]

Personalized medicine is more than targeted therapeutics

That’s a message Enzo Biochem (NYSE:ENZ) wants to get out. “We are positioned extremely well for personalized medicine in the sense that as new immunoassays are recommended by the various professional societies, we are able to move them into the market very quickly because of our broad range of technology and licensure,” David Goldberg, VP [...]

Helix BioPharma has positive interim Phase 2 results

The first 10 patients enrolled in Helix BioPharma’s Phase 2 pharmacokinetic study of topical interferon Alpha-2b, in patients with low-grade cervical lesions, have completed the pharmacokinetic primary end point analyses with positive findings. “Given the uniformity of the primary endpoint findings to-date, we intend to conclude patient recruitment for this study once a total of [...]